Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections

Current Opinion in Rheumatology

Volumn 19, Issue 6, 2007, Pages 619-625

  Vassilopoulos, Dimitrios ^a   Calabrese, Leonard H ^b,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antirheumatic agents; Hepatitis B virus; Hepatitis C virus; HIV; JC virus; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ADEFOVIR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; ENTECAVIR; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; NATALIZUMAB; NUCLEOSIDE; PREDNISONE; RIBAVIRIN; RITUXIMAB; STEROID; TELBIVUDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; CLINICAL TRIAL; CROHN DISEASE; CRYOGLOBULINEMIA; DISEASE COURSE; EPSTEIN BARR VIRUS; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; CHRONIC DISEASE; HEPACIVIRUS; HEPATITIS B VIRUS; HERPESVIRUS 3, HUMAN; HERPESVIRUS 4, HUMAN; HIV; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; RHEUMATIC DISEASES; VIRUS ACTIVATION; VIRUS DISEASES;

EID: 34948850781     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f05b63     Document Type: Review

References (29)

1. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 (Suppl 2):ii18-ii24.
2. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004; 17:365-370.
3. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127:467-470.
4. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369-374.
5. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375-381.
6. Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol 2006; 19:341-349.
7. Rituximab. FDA Alert [12/06]. Available at: http://www.fda.gov/cder/drug/ InfoSheets/HCP/rituximab.pdf. Accessed 24 June 2007.
8. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007; 56:2116-2128. A systematic review of PML in all rheumatic diseases including clinical findings and approach to diagnosis.
9. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
10. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43:209-220.
11. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24:1003-1016. Recent systematic review on the role of lamivudine prophylaxis in patients with chronic HBV treated with chemotherapy.
12. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65:983-989. Recent literature review of the effect of immunosuppressive medications on HBV replication in patients with rheumatic diseases. An algorithm for the screening and treatment of these patients is also outlined.
13. Tsai FC, Hsieh SC, Chen DS, et al. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci 2006; 51:1627-1632.
14. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30:1624-1625.
15. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62:686-687.
16. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363-1365.
17. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31:107-109.
18. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005; 52:2519-2520.
19. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50:163-166.
20. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64:788-789.
21. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12:974-976.
22. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45:1294-1297. An open study of 6 patients with chronic HBV or HCV infection treated with anti-TNF agents.
23. Sakellariou GT, Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007; 26:950-952.
24. Tsochatzis E, Vassilopoulos D, Manesis EK, et al. First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. Scand J Gastroenterol 2007; 42:784-785.
25. Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83:769-774.
26. Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155:1053-1056.
27. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344:68-69.
28. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13:2436-2441.
29. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis. Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002; 46:585-597.